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The activity of roxithromycin was determined by a microdilution method, in
comparison with erythromycin, spiramycin and josamycin. Roxithromycin and
erythromycin showed very similar MICs against staphylococci, Streptococcus
pneumoniae, Str. pyogenes and Haemophilus influenzae. In most cases, spiramycin
and josamycin appeared similarly or more active. The activity of roxithromycin
against Mycoplasma pneumoniae, Legionella spp., Chlamydia psittaci and, to some
extent, against Pastewella spp. was also assessed, by suitable in-vitro methods.
Roxithromycin has a promising potential for treating selected skin and respiratory
infections.
Introduction
Erythromycin is a macrolide antibiotic which is useful for therapy of respiratory and
skin infections caused by susceptible micro-organisms such as Staphylococcus,
Streptococcus, Mycoplasma, Chlamydia and Legionella spp. Roxithromycin is a new
ethero oxime derivative of erythromycin (Jones, Barry & Thomsberry, 1983) with
improved pharmacokinetic properties. This report compares the in-vitro activity of
roxithromycin, erythromycin, josamycin, and spiramycin against different micro-
organisms causing skin or respiratory infections.
Materials and methods
Personal studies
A total of 247 bacterial isolates were collected by the Laboratoire Central de
Bacteriologie or, occasionally, in other Swiss hospitals. These isolates included 56
Staph. aureus, 26 Staph. epidermidis, 24 Staph. saprophyticus, 62 Str. pneumoniae, 38
Str. pyogenes, 20 Haemophilus influenzae and 21 Nocardia asteroides. The above
bacteria were typical strains, according to conventional identification methods. They
were kept frozen in skim milk at — 70°C. Before study, organisms were thawed,
streaked on to sheep blood agar and incubated overnight at 35°C. Standard antibiotic
powders were obtained from their respective manufacturers. Antibiotic working
solutions were prepared according to the instructions of the manufacturer and used
immediately after appropriate dilution in water or in broth.
Antimicrobial activity was measured in most cases by a microdilution method in
Mueller-Hinton broth, following the M7-T procedure specified by the National
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Committee for Clinical Laboratory Standards (1983). The final inoculum of
105-106 cfu/ml was prepared from a trypticase soy broth inoculated 4 h before and
controlled by viable counts. The inoculum for H. influenzae was prepared and tested in
Brain Heart Infusion broth supplemented with 5% nicotinamide diphosphate and 10%
haemin. For all strains, except N. asteroides, the MIC was read after 18 h of
incubation at 35°C. N. asteroides was tested by agar dilution on Mueller-Hinton agar
with 10* cfu/spot with 35°C incubation for three days. In all cases, the MIC was
defined as the lowest antibiotic concentration yielding no growth visible to the nalced
eye.
Other studies
For completion of this study, and after permission from their respective authors, some
reports prepared for Roussel Uclaf, Paris, are quoted here. These reports and their
methods follow. C. Bebear (Hopital Pellegrin Bordeaux, France) studied ten strains of
M. pneumoniae, and determined the MIC of macrolides in agar dilution (Hayflick
medium, pH 7-2, containing 20% of foal serum). K. Suzaki and Y. Niitu (The
Research Institute for Tuberculosis and Cancer, Tohoku University, Japan) tested the
growth inhibitory effect of roxithromycin on M. pnevmoniae by a microdilution
method using a standard mycoplasma broth (pH 7-6) without penicillin but with
phenol red. J. Fleurette determined the MIC of roxithromycin for 98 strains of
Legionella spp. (30 reference strains from the CDC, Atlanta, Georgia, U.S.A.,
representative of 15 different species and various serotypes; 34 strains of clinical origin;
34 strains from the environment). This study was carried out by using the antibiotic
medium No. 1 (Oxoid), supplemented with iron pyrophosphate (0-25 g/1) and L-cystein
hydrochloride (0-4 g/1). Three other reports, respectively by I. D. Farrell (Public Health
Laboratory service, East Birmingham Hospital, England), A. Bure (Hopital Claude
Bernard, Paris, France) and J. Acar (Hopital Saint Joseph, Paris, France) also dealt
with Legionella spp., but used BCYE medium (broth or agar). J. Orfila (C.H.U.,
Amiens, France) studied growth inhibition of C. psittaci by macrolides and
tetracyclines in a cell line (HELA 229). R. C. Spencer, Royal Hallamshire Hospital,
Sheffield, England, determined the activity of roxithromycin against 10 strains of
Pasteurella spp. isolated from skin infections.
Results and discussion
Staph. aureus
The collection of Staph. aureus was divided into three categories according to the
activity of benzyl-penicillin and oxacillin (Table I). Roxithromycin appeared active
(MIC100 2 mg/1) against the strains that were susceptible to these two /Mactam
compounds, confirming previous studies (Jones, Barry & Thornsberry, 1983; Rolston,
Le Blanc & Ho, 1986). Roxithromycin was also active against all strains that were
resistant to benzylpenicillin (MIC > 32 mg/1) and susceptible to oxacillin. Generally, in
this collection, the activity of roxithromycin was comparable with that of erythromycin
within one dilution, with the exception of three strains for which the MIC of
erythromycin was four to eight times higher than that of roxithromycin. Spiramycin
and josamycin appeared to be slightly more active than erythromycin and
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Table 1. Activity of macrolides against skin and respiratory pathogens (personal data)
Organisms
(number)
Penicillin-sensitive
Staph. aureus (IS)
Penicillin-resistant
oxacillin-sensitive
Staph. aureus {\9)
Oxacillin-resistant
Staph. aureus (20)
Staph. epidermidis (26)
Staph. saprophytiau (24)
Str. pneumoniae (62)
Str. pyogenes (38)
H. influenzae (20)
N. asteroides (21)
Antibiotic
roxithromycin
erythromycin
spiramycin
josamycin
roxithromycin
erythromycin
spiramycin
josamycin
roxithromycin
erythromycin
spiramycin
josamycin
roxithromycin
erythromycin
spiramycin
josamycin
roxithromycin
erythromycin
spiramycin
josamycin
roxithromycin
erythromycin
spiramycin
josamycin
roxithromycin
erythromycin
spiramycin
josamycin
roxithromycin
erythromycin
spiramycin
josamycin
roxithromycin
MIC50
(mg/1)
1
2
0-5
0-25
2
4
1
0-25
128
128
1
0-5
0-5
1
0-25
0-25
0-5
1
0-25
0-5
0-4
0-8
0-2
01
0-25
0-25
006
0125
8
8
8
8
128
MIC,0
(mg/1)
2
4
1
1
2
4
1
0-5
128
128
128
128
128
128
0-25
0-25
32
16
0-5
2
0-4
1-6
0-8
0-2
0-25
0-5
006
0125
8
8
8
8
128
Range
(mg/1)
0-5-2
1-16
0-25-1
0-25-0-5
1-2
2-4
0-5-1
0-25-0-5
l - > 128
2 - > 128
0-5- > 128
0-25- > 128
0-25-128
006-128
006-128
0125-128
0-25-32
0-5-64
0-125-1
0-25-2
0-025-12-8
0-1-6-4
0012-3-2
0-025-0-4
0-06-0-25
0-125-0-5
006-006
006-0125
1-8
1-8
2-8
2-16
0-25- > 128
roxithromycin. The phenotype of resistance was strikingly different when we dealt
with the oxacillin resistant strains (MIC > 32 mg/1). Eighteen of the 20 oxacillin
resistant strains were also resistant to erythromycin and roxithromycin. The general
trend towards higher macrolide MICs among the oxacillin-resistant Staph. aureus is a
known fact (Lyon & Skurray, 1987), already observed with roxithromycin (Jones
et al., 1983; Rolston et al., 1986). As an exception, two oxacillin resistant
Staph. aureus were susceptible to the four macrolides tested. Besides, ten of 20
oxacillin resistant Staph. aureus demonstrated a so called dissociated phenotype of
resistance, according to the terminology initially proposed by Garrod (1957): they were
resistant to erythromycin, but sensitive to spiramycin and josamycin. Strains exhibiting
the dissociated phenotype are now known to be inducibly resistant to all the MLSB
(Macrolides, Lincosamides, Streptogramin type B) group of antibiotics via a
methylation mediated by small multicopy plasmids (Weisblum, 1985). Our study shows
that roxithromycin behaves as erythromycin and not as the two other macrolides in
this respect.
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Coagulase-negative staphylococci
Among the 26 strains of Staph. epidermidis tested, 19 were susceptible (MIC < 2 mg/1)
to the four macrolides tested, five expressed the dissociated phenotype, and two
exhibited generalized (Garrod, 1957) resistance. On a weight basis, activity of
erythromycin and roxithromycin were comparable within one dilution, while
spiramycin and josamycin were two to eight times more potent. As reported by Jones
et al. (1983), no significant differences were found in the MICs for the Staph.
epidermidis, whether or not they produced penicillinase. As to Staph. saprophyticus, 20
of 24 strains were susceptible to the four macrolides, whereas four strains showed a
dissociated phenotype of resistance.
Streptococci
Among the streptococci, Str. pneumoniae and Str. pyogenes are the most frequently
involved in respiratory and skin infections. Sixty-one of 62 strains of Str. pneumoniae
appeared to be sensitive to achievable concentrations of the four macrolides, but one
strain made an exception, exhibiting a quite resistant pattern. Here, the MICs were
respectively 12-8 mg/1 for roxithromycin, 6-4 mg/1 for erythromycin, 3-2 mg/1 for
spiramycin and 0-4 mg/1 for josamycin. All 38 strains of Str. pyogenes appeared to be
susceptible to the four macrolides, with similar activities of the compounds on a weight
basis. In the report by R. C. Spencer however, one erythromycin-resistant Str.
pyogenes was also resistant to roxithromycin, and similar observations are reported in
the literature (Jones et al., 1983; Barlam & Neu, 1984).
H. influenzae
Roxithromycin and the three other macrolides showed consistent, although modest,
antimicrobial activity against type b (14 strains) and non-type b (6 strains)
H. influenzae. The results reported in this study regarding the specific activity of
roxithromycin against H. influenzae are similar to the findings of Jones et al. (1983)
and Jorgensen, Redding & Howell (1986), but slightly less favourable than those
reported by Barlam & Neu (1984) or by Chantot, Bryskier & Gasc (1986).
Other bacteria
C. Bebear, dealing with ten strains of M. pneumoniae, reports that MICs were
< 0-01 mg/1 for both erythromycin and roxithromycin in all cases. The report by
K. Suzaki and Y. Niitu revealed that the strains resistant to erythromycin had a
similar degree of resistance to roxithromycin.
According to J. Fleurette's report, the MIC100 of different species of Legionella were
as follows: 0-25 mg/1 for roxithromycin, 0-5 mg/1 for erythromycin and 1 mg/1 for
josamycin. This favourable activity was also reported by J. F. Acar, A. Bure and
I. D. Farrell. Using her model of cell culture against C. psittaci, J. Orfila showed that
roxithromycin had an activity (inhibition of bacterial growth) starting at a
concentration of 0-5 mg/1. This activity was shown after 24 h of contact, increasing
after 48 h and 72 h, and was comparable with that of erythromycin, josamycin,
tetracycline and minocycline. R. C. Spencer showed that the MICJ0 and MIC90 of
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erythromycin and roxithromycin against Pasteurella spp. were 4 mg/1 for both drugs
(range of MICs, 0-5-4 mg/1).
In conclusion, macrolides such as erythromycin have a good activity against
staphylococci, streptococci, some Haemophilus strains, Legionella spp. and C. psittaci
and have been extremely useful in diseases caused by these organisms. They have been
recommended for upper respiratory infections, such as otitis, sinusitis, or eradication
of group A streptococci from the throat. Erythromycin is the standard therapy for
M. pneumoniae and legionella pulmonary infection. Also, macrolides are indicated in
mild respiratory or skin infections caused by streptococci or staphylococci, as an
alternative to /Mactams in penicillin-allergic patients.
Roxithromycin, which shows antibacterial activity very similar to that of
erythromycin, is reported to have more favourable pharmacokinetic properties than
erythromycin. Roxithromycin could, therefore, be a useful antibiotic in selected skin
and respiratory infections.
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